Soliris Successfully Treats aHUS in COVID-19 Patient With Heart Transplant
Soliris (eculizumab) was shown to effectively treat atypical hemolytic uremic syndrome (aHUS) triggered by COVID-19 in a patient who had undergone a heart transplant five years earlier, according to a recent case report study. “We present a case of [a] 32-year-old Hispanic male with a history of heart…